©1996-2011 All
Rights
Reserved. Online Journal of Bioinformatics . You may not store these pages in
any form except for
your own personal use. All other usage or distribute on is illegal
under
international copyright treaties. Permission to use any of these pages
in any
other way besides the before mentioned
must
be gained in writing from the publisher. This article is exclusively
copyrighted in its entirety to OJB publications. This article may be
copied
once but may not be, reproduced or re-transmitted
without the
express permission of the editors. This
journal
satisfies the refereeing requirements (DEST) for the Higher Education
Research Data Collection (Australia). Linking:To link
to
this page or any pages linking to this page you must link directly to
this
page only here rather than put up your own page.
OJBTM
Online Journal of
Bioinformatics ©
Volume
12(1):57-65,
2011
Inhibition
of Farnesyl pyrophosphate by allosteric site drug binding
Satish kumar(Msc), Jyoti
Pathak(Msc), Asha(Msc), Rajib
Bandopadhyay(PhD)
*,Department
of
Biotechnology, Birla Institute of Technology, Mesra,
Ranchi-835215,
Jharkhand, India
ABSTRACT
Kumar S, Pathak J, Asha
PJ, Bandopadhyay R, Inhibition of Farnesyl
pyrophosphate by allosteric site drug
binding, Online
J Bioinformatics, 12(1):57-65, 2011 . Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by defective lamin A protein
which remains farnesylated after post
translational modification. Zoledronate is
a potent farnesyl
pyrophosphate synthase inhibitor. A total
of 45
compounds selected from the Zinc database were docked on protein FPPS
through
GLIDE and their ADME score were calculated from QikProp.
The analysis suggests that ZINCID13678562, could be used as an alternative
to Zoledranate if confirmed by In
Vivo pharmacology.
Keywords: - Progeria, Zoledronate,
GLIDE, ADME, FPPS.